MS-553

Small molecule

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

Also in development:Diabetic Macular Edema · Phase 1

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1/2 (4)
Chronic Lymphocytic Leukemia
NCT06979076 · MingSight Pharmaceuticals, Inc
2026-07 – 2028-12 · CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma)
What this study did
NCT05720052 · MingSight Pharmaceuticals, Inc
2023-02-06 – 2023-11-28 · Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Marginal Zone Lymphoma (MZL)
What this study did
NCT03492125 · MingSight Pharmaceuticals, Inc
2018-05-25 – 2023-11-28 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma
What this study did
Other / comorbidity
NCT05272813 · Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.
2022-04-28 – 2023-11-28 · Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
Phase 1 (2)
Diabetic Macular Edema
Other / comorbidity
NCT02406989 · MingSight Pharmaceuticals Pty Limited
2015-04 – 2015-09 · Safety and PK in Healthy Volunteers
What this study did

Competitive landscape

This drug's own stage for Chronic Lymphocytic Leukemia: Phase 1/2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
MS-553: this drugPhase 1/2Small moleculeProtein kinase C-beta (PKC-beta)not yet gradedNo reviewed efficacy summary in this indication
AcalabrutinibApprovedSmall moleculeBTKPartial signalFeatured results are non-efficacy only in this race
AlemtuzumabApprovedMonoclonal antibodyCD52not yet gradedNo reviewed efficacy summary in this indication
IbrutinibApprovedSmall moleculeBTKPartial signal
NCT01611090: Progression-free Survival (PFS) (Up to 5 years): Ibrutinib+BR 65.12 Months | Placebo+BR 14.32 Months (95% CI 13.86 to 16.62)
ObinutuzumabApprovedMonoclonal antibodyCD20Partial signalNo reviewed efficacy summary in this indication
PF-05280586ApprovedBiologic (subtype unspecified)CD20not yet gradedNo reviewed efficacy summary in this indication
PirtobrutinibApprovedSmall moleculeBTKPartial signalFeatured results are non-efficacy only in this race
Rituximab (Rituxan)ApprovedMonoclonal antibodyCD20, CD20-directed Cytolytic Antibodynot yet gradedNo reviewed efficacy summary in this indication
Rituximab-Abbs (Truxima)ApprovedMonoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
VenetoclaxApprovedSmall moleculeBCL-2Partial signal
NCT02005471: Investigator-assessed PFS, venetoclax-rituximab vs bendamustine-rituximab: 2-year rates 84.9% vs 36.3% (hazard ratio 0.17; P<0.001)
Zanubrutinib (Brukinsa)ApprovedSmall moleculeBTKPartial signal
NCT03734016: Overall response rate, zanubrutinib (n=327) vs ibrutinib (n=325): by independent review 86.2% vs 75.7%, response ratio 1.14 (95% CI 1.05 to 1.22), non-inferiority p<0.0001, superiority p=0.0007; by investigator 83.5% vs 74.2%, response ratio 1.12 (95% CI 1.04 to 1.22), non-inferiority p<0.0001, superiority p=0.0035 (CT.gov posted results).
BexobrutidegPhase 3Small moleculeBruton's tyrosine kinase (BTK)not yet gradedNo reviewed efficacy summary in this indication
NemtabrutinibPhase 3Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Sonrotoclax (Beqalzi)Phase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MesutoclaxPhase 2/3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow MS-553 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
September 2028 (1)
Phase 1/2Chronic Lymphocytic LeukemiaNot yet recruiting
Est. primary completion 2028-09 · NCT06979076 · CT.gov ↗
What to watch

See the full readout calendar ↗